Meningococcal Vaccination: o Administer Menveo (MenACWY) and either Bexsero or Trumenba (MenB) at least 2 weeks prior to administering the first dose of eculizumab Prophylactic antibiotics may be administered in addition to vaccination for the duration of the eculizumab treatment at the discretion of the Infectious Diseases service Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. • Should continue meningococcal vaccination of all patients who receive eculizumab. • Should administer meningococcal vaccines at least 2 weeks prior to administering the first dose of eculizumab, unless the risks of delaying eculizumab therapy outweigh the risks of developing a meningococcal infection, according to the product label. Meningococcal ACWY Vaccine Recommendations by Age and Risk Factor footnotes 1. Use of eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a 1,000-fold to 2,000-fold increased incidence of meningococcal disease (1). Meningococcal disease is caused by bacteria called Neisseria meningitidis. Should he receive meningococcal vaccine? (see The disease strikes quickly and can have serious complications, including death. Sepsis is a common presentation of 6.If available, use the same vaccine product for all doses in 4. the series given to infants, including the booster doses. Administration of meningococcal vaccines is recommended for patients receiving eculizumab before beginning treatment (2,3). Eculizumab (Soliris) and the related long-acting compound, ravulizumab (Ultomiris) bind to C5 and inhibit the terminal complement pathway. to 10 years receive the meningococcal conjugate vaccines (Menactra and Menveo) if any of the following special conditions are present 4: complement component deficiency, damaged spleen or asplenia, HIV, residing or traveling near a meningococcal disease outbreak, taking Soliris, or traveling to places where meningitis is common. The meningococcal vaccine protects you from four types of bacteria that cause meningococcal disease. Vaccination may not be sufficient to prevent meningococcal infection. When the linings of the brain and spinal cord become infected, it is called meningitis. Consideration should be given to official guidance on the appropriate use of antibacterial agents. They result in a decrease in meningitis and sepsis among populations where they are widely used. It can lead to serious blood infections. Practices (ACIP) recommendations for meningococcal vaccination in patients with complement deficiencies (5.1). The vaccines are between 85 and 100% effective for at least two years. The risk for meningococcal disease remains high in patients using the blood disorder drug Soliris, even after they have received a meningococcal vaccine, according to CDC researchers. Due to the increased risk of meningococcal infections, meningococcal vaccination is recommended at least 2 weeks prior to receiving eculizumab, unless the risks of delaying eculizumab therapy outweigh the risk of developing a meningococcal infection, in which case the meningococcal vaccine should be administered as soon as possible. Cases of serious or fatal meningococcal infections have been reported in Soliris-treated patients. A review of eculizumab recipients in the United States from 2008 to 2016 identified 16 cases of meningococcal disease with eleven cases caused by nongroupable Neisseria meningitidis not impacted by vaccination. 2. system disorder or by taking a complement inhibitor Seek advice of local public health authorities to determine if vaccination is recommended. • Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of Soliris unless the risks of delaying Soliris therapy outweigh the risk s of developing a meningococcal infection. Vaccination reduces but does not eliminate the risk of meningococcal infections. Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitidis.